Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
New Biofermin S Tablets
- Development stage
- Unknown
- Lead developer
- Taisho Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
New Biofermin S Tablets is a probiotic product developed by Biofermin Pharmaceutical (a subsidiary of Taisho Pharmaceutical) and marketed in Japan as a designated quasi-drug. It contains a combination of three live lactic acid bacteria strains: *Bifidobacterium bifidum*, *Enterococcus faecalis*, and *Lactobacillus acidophilus*. These strains are specifically selected to colonize different regions of the human gastrointestinal tract—the large intestine and the small intestine—where they produce lactic acid and acetic acid. This action helps to suppress the growth of harmful bacteria, balance the gut microbiome, and improve symptoms such as constipation, loose stools, and abdominal bloating. The "New" (Shin) formulation is an evolution of the original Biofermin product, optimized for better bacterial viability and intestinal regulation.
- Brand names
- New Biofermin S TabletsShin Biofermin S
- Other names
- New Biofermin S
Beyond the preview
Go deeper on New Biofermin S Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New Biofermin S Tablets.